Insider Buying: HeartBeam (NASDAQ:BEAT) Director Purchases $600,000.00 in Stock

HeartBeam, Inc. (NASDAQ:BEAT) Director Mark Strome acquired 750,000 shares of the firm’s stock in a transaction dated Thursday, April 16th. The stock was bought at an average price of $0.80 per share, with a total value of $600,000.00. Following the acquisition, the director directly owned 3,650,000 shares in the company, valued at $2,920,000. This represents a 25.86% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.

HeartBeam Price Performance

Shares of NASDAQ BEAT opened at $0.92 on Friday. The stock has a market capitalization of $37.80 million, a price-to-earnings ratio of -1.48 and a beta of -0.63. The business has a 50-day moving average of $1.29 and a 200-day moving average of $1.61. HeartBeam, Inc. has a fifty-two week low of $0.54 and a fifty-two week high of $4.00.

HeartBeam (NASDAQ:BEAT) last announced its quarterly earnings data on Thursday, March 12th. The medical research company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.01).

Hedge Funds Weigh In On HeartBeam

Hedge funds and other institutional investors have recently bought and sold shares of the business. Insigneo Advisory Services LLC bought a new position in HeartBeam during the fourth quarter worth about $74,000. Virtu Financial LLC bought a new position in HeartBeam during the fourth quarter worth about $70,000. Jane Street Group LLC bought a new position in HeartBeam during the fourth quarter worth about $55,000. Raymond James Financial Inc. grew its holdings in HeartBeam by 102.2% during the second quarter. Raymond James Financial Inc. now owns 28,178 shares of the medical research company’s stock worth $35,000 after purchasing an additional 14,242 shares during the period. Finally, CIBC Private Wealth Group LLC bought a new position in HeartBeam during the fourth quarter worth about $26,000. Institutional investors own 7.77% of the company’s stock.

Key Stories Impacting HeartBeam

Here are the key news stories impacting HeartBeam this week:

• Positive Sentiment: Multiple senior insiders bought substantial stakes (totaling ~1.12M shares at $0.80/share), including director Mark E. Strome’s 750,000‑share purchase — a strong signal of management confidence that likely helped lift the stock. Read More.
• Positive Sentiment: Director Marga Ortigas‑Wedekind separately disclosed a 25,000‑share buy at $0.80, reinforcing the pattern of insider accumulation. Read More.
• Neutral Sentiment: Recent articles comparing HeartBeam to peers provide background on competitive positioning and product opportunities (useful for longer‑term investors but not an immediate catalyst). Read More.
• Negative Sentiment: HeartBeam closed a $10.0M public offering to fund commercialization and AI initiatives — the cash reduces funding risk but the equity issuance is dilutive and often depresses short‑term share prices. Media coverage noted selling pressure around the offering. Read More.

Analyst Ratings Changes

A number of analysts have commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $5.50 price target on shares of HeartBeam in a research note on Monday, March 16th. Wall Street Zen cut shares of HeartBeam to a “strong sell” rating in a research note on Saturday, January 3rd. D. Boral Capital started coverage on shares of HeartBeam in a research note on Friday, March 27th. They issued a “buy” rating and a $5.00 price target for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of HeartBeam in a report on Monday, December 29th. Finally, B. Riley Financial started coverage on HeartBeam in a report on Tuesday, March 31st. They set a “buy” rating and a $4.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $4.80.

About HeartBeam

BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors.